Neuroendocrine Tumor Articles & Analysis
6 news found
Food and Drug Administration (FDA) has granted the company Fast Track designation for ITM-11 (n.c.a. 177Lu-edotreotide), an investigational radiopharmaceutical for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM-11 is being evaluated as a Targeted Radionuclide Therapy in two phase III clinical trials, COMPETE and COMPOSE. ...
SERB is pleased to announce it has acquired the rights from Ipsen to commercialize Xermelo® (telotristat ethyl) in Europe and other countries outside the US and Japan. Financial terms of the transaction were not disclosed. Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea (CSD) in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by ...
Curasight A / S ("Curasight" or "The Company") announces today that it is expanding and accelerating its clinical programs with two additional cancer indications - Neuroendocrine tumors (NET) and head and neck cancer. Both indications will be pursued with regard to both diagnostics and therapy meaning that Curasight strengthens its position as a theranostic ...
The collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers. Dr. Steven K. Libutti, Director of Rutgers Cancer Institute of New Jersey, Vice Chancellor of Cancer Programs, Rutgers Biomedical and Health Sciences, and Senior Vice President of ...
The study demonstrates strong prognostic value and that uPAR is expressed in the majority of neuroendocrine tumor patients. The abstract of the article is freely available here (https://pubmed.ncbi.nlm.nih.gov/35058319/). The phase II study The phase II trial (NCT03278275) aimed to evaluate the expression of uPAR in neuroendocrine ...
Camurus (NASDAQ STO: CAMX) today announces that dosing has been initiated in the company’s randomized, active-controlled Phase 3 study, SORENTO, which aims to evaluate the efficacy and safety of octreotide subcutaneous depot (CAM2029) in the treatment of patients with neuroendocrine tumors localized in the gastrointestinal tract or pancreas (GEP-NET). ...